ArticleBMC gastroenterology2025
Association between albumin-corrected anion gap and delirium in acute pancreatitis: insights from the MIMIC-IV database.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Albumin-corrected anion gap and 28-/90-day mortality in cirrhotic patients with invasive fungal infection: a retrospective cohort study.BMC infectious diseases · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDelirium frequently occurs as a severe complication among patients with acute pancreatitis (AP), contributing to extended hospital stays, higher mortality rates, and lasting cognitive deficits. The pathogenesis of delirium in this setting is strongly influenced by metabolic abnormalities, including disturbances in electrolyte balance and widespread inflammation. Although the albumin-corrected anion gap (ACAG) is a recognized indicator of metabolic dysfunction, its relevance to delirium in AP patients has not been adequately investigated.
methodsThis study utilized patient records from the MIMIC-IV database to investigate how ACAG relates to the onset of delirium in individuals with acute pancreatitis. Analytical approaches included the use of summary statistics, Kaplan-Meier survival analyses, receiver operating characteristic (ROC) curve evaluation, and both univariable and multivariable Cox proportional hazards models. To capture potential nonlinear effects, restricted cubic spline (RCS) modeling was implemented. Subgroup analyses were conducted to examine possible demographic and clinical effect modifiers. Additionally, several machine learning algorithms-such as the Random Forest-were employed to further evaluate the predictive power of ACAG.
resultsElevated levels of ACAG were independently linked to an increased likelihood of developing delirium during both the 28-day hospitalization period and throughout the ICU stay. Results from the multivariable Cox proportional hazards analysis indicated that each incremental rise in ACAG was associated with a greater risk of delirium (hazard ratio: 1.06, 95% confidence interval: 1.02-1.10, p < 0.001). The application of restricted cubic spline modeling verified the linear nature of this association. Among the machine learning models, the Random Forest achieved superior predictive accuracy (AUC = 0.81), and SHAP analysis highlighted ACAG as a primary determinant in model prediction.
conclusionsThe ACAG emerged as an independent predictor of delirium among individuals with acute pancreatitis, displaying a linear association with the risk of delirium onset. When compared to other commonly used biomarkers, ACAG exhibited enhanced predictive capacity for identifying patients at risk. These findings suggest that ACAG could serve as a practical clinical marker for the early detection and prompt management of delirium in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.